PAVmed Statistics
Total Valuation
PAVmed has a market cap or net worth of $8.10 million. The enterprise value is $14.30 million.
Important Dates
The next confirmed earnings date is Thursday, August 14, 2025, before market open.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PAVmed has 17.62 million shares outstanding. The number of shares has increased by 879.09% in one year.
| Current Share Class | 17.62M |
| Shares Outstanding | 17.62M |
| Shares Change (YoY) | +879.09% |
| Shares Change (QoQ) | -60.22% |
| Owned by Insiders (%) | 7.62% |
| Owned by Institutions (%) | 6.86% |
| Float | 12.48M |
Valuation Ratios
The trailing PE ratio is 0.48.
| PE Ratio | 0.48 |
| Forward PE | n/a |
| PS Ratio | 2.53 |
| Forward PS | 55.76 |
| PB Ratio | 0.42 |
| P/TBV Ratio | 0.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 0.20 |
| EV / Sales | 7.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.37, with a Debt / Equity ratio of 0.23.
| Current Ratio | 0.37 |
| Quick Ratio | 0.31 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,087.79 |
Financial Efficiency
Return on equity (ROE) is 644.12% and return on invested capital (ROIC) is -56.60%.
| Return on Equity (ROE) | 644.12% |
| Return on Assets (ROA) | -49.81% |
| Return on Invested Capital (ROIC) | -56.60% |
| Return on Capital Employed (ROCE) | -83.40% |
| Revenue Per Employee | $51,103 |
| Profits Per Employee | $1.86M |
| Employee Count | 39 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 6.73 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.50% in the last 52 weeks. The beta is 1.08, so PAVmed's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | -42.50% |
| 50-Day Moving Average | 0.58 |
| 200-Day Moving Average | 0.72 |
| Relative Strength Index (RSI) | 35.30 |
| Average Volume (20 Days) | 254,508 |
Short Selling Information
The latest short interest is 211,296, so 1.20% of the outstanding shares have been sold short.
| Short Interest | 211,296 |
| Short Previous Month | 229,832 |
| Short % of Shares Out | 1.20% |
| Short % of Float | 1.69% |
| Short Ratio (days to cover) | 1.94 |
Income Statement
In the last 12 months, PAVmed had revenue of $1.99 million and earned $72.45 million in profits. Earnings per share was $0.96.
| Revenue | 1.99M |
| Gross Profit | -1.14M |
| Operating Income | -35.90M |
| Pretax Income | -61.46M |
| Net Income | 72.45M |
| EBITDA | -35.24M |
| EBIT | -35.90M |
| Earnings Per Share (EPS) | $0.96 |
Full Income StatementBalance Sheet
The company has $3.05 million in cash and $9.24 million in debt, giving a net cash position of -$6.19 million or -$0.35 per share.
| Cash & Cash Equivalents | 3.05M |
| Total Debt | 9.24M |
| Net Cash | -6.19M |
| Net Cash Per Share | -$0.35 |
| Equity (Book Value) | 40.93M |
| Book Value Per Share | 1.09 |
| Working Capital | -6.14M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$22.03 million and capital expenditures -$19,000, giving a free cash flow of -$22.05 million.
| Operating Cash Flow | -22.03M |
| Capital Expenditures | -19,000 |
| Free Cash Flow | -22.05M |
| FCF Per Share | -$1.25 |
Full Cash Flow StatementMargins
Gross margin is -57.15%, with operating and profit margins of -1,801.15% and 3,711.54%.
| Gross Margin | -57.15% |
| Operating Margin | -1,801.15% |
| Pretax Margin | 3,289.61% |
| Profit Margin | 3,711.54% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PAVmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -879.09% |
| Shareholder Yield | -879.09% |
| Earnings Yield | 893.96% |
| FCF Yield | -272.02% |
Dividend DetailsAnalyst Forecast
The average price target for PAVmed is $19.00, which is 4,030.44% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.00 |
| Price Target Difference | 4,030.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 153.17% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on December 7, 2023. It was a reverse split with a ratio of 1:15.
| Last Split Date | Dec 7, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
PAVmed has an Altman Z-Score of -8.07 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.07 |
| Piotroski F-Score | 2 |